Search results
Showing 1651 to 1700 of 1968 results for news
We provide an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care.
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.
Licensing and Access Pathway (ILAP) Early access to medicines scheme (EAMS) A new model for evaluating and purchasing antimicrobials in...
Supporting the health and care system to implement virtual wards
Virtual wards (also known as hospital at home) provide hospital level care at home.
If you’re unsure where to start or your circumstances are unique, we encourage you to get in touch. We’ll work with you to unpick your challenges and find a solution that meets your needs.
How NICE uses cookies and how you can manage them.
We've recently launched a new NICE website. Following a content review, a number of pages and sections have not moved onto the...
Support for delivering quality, safety and efficiency in the optimisation of medicines.
Tell us about an interventional procedure you think should be assessed by NICE.
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.
Information and links to key resources that will help you keep your practice up-to-date.
requirements concerning ivacaftor/tezacaftor/elexacaftor. 2.2 This Agreement and the new terms herein will commence on the date of...
Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.
We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.
Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.
Learn more about our updated maternal and child nutrition guideline
Home News Podcasts Learn more about our updated maternal and child nutrition guideline Podcasts 30 May 2025 Listen About this episode...
Home News Podcasts Will robotic-assisted surgery change NHS practice forever? Podcasts 30 April 2025 Listen About this episode In this...
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
Health inequalities - an update to NICE's methods for health technology evaluation
Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
AI skin cancer detection system gets green light for conditional NHS use
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected.
Technology recommended for people with chronic tic disorders and Tourette syndrome
Final guidance recommends one digital therapy to help children and young people manage their condition.
New guideline will help cut falls and related hospital admissions for older and at-risk people
Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.
Health Check to create a business case. This asks the council to introduce new systems and opportunities for social workers to promote...
proposing to relocate locality teams to a number of health centres, as part of a new integrated support service. The team managers are...
Cutting-edge robotic surgery gets green light as 11 systems are recommended
Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
Millions of people living with long-term neurological conditions across England face inconsistent access to vital rehabilitation services, according to NICE.
Updated pneumonia guidelines for babies and children with mild pneumonia
Babies and children between the ages of three months and 11-years-old with pneumonia should be offered a three-day rather than five-day course of antibiotics, according to a new draft NICE guideline.
Home News Podcasts Navigating the future - AI at NICE Podcasts 28 February 2025 Listen About this episode Dr Pall Jonsson, programme...
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
First-ever NHS treatment approved for advanced Hodgkin lymphoma
New combination therapy offers hope to 800 people annually with late-stage blood cancer.
Home News Podcasts NICE's positive recommendations for lung cancer treatments Podcasts 20 January 2025 Listen About this episode We're...
Endometriosis - learn more about NICE's guideline for this chronic condition
Home News Podcasts Endometriosis - learn more about NICE's guideline for this chronic condition Podcasts 25 March 2025 Listen About this...
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
Changes approved to the routing criteria for highly specialised technologies
At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
Annual BMI checks recommended for adults with long-term conditions
We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.
Harnessing expertise to improve patient access to innovative health technologies
Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
NICE approves groundbreaking one-off gene therapy for severe sickle cell disease
People in England with severe sickle cell disease will be among the first to receive treatment using revolutionary CRISPR gene editing technology, following publication of our final draft guidance today.
New option for adult leukaemia patients as we recommend treatment
Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
New life-changing treatment option recommended for type of rare epilepsy
This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.